Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
AMSBIO has extended its COVID-19 research portfolio with the introduction of a service to provide custom lentivirus pseudotyped with spike glycoprotein from SARS-CoV-2 to help researchers identify potential targets for development of therapeutic drugs and vaccines.
Various research groups around the world have demonstrated that SARS-CoV-2 uses its spike glycoprotein S, a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry.
In response to the COVID-19 outbreak, A4P Bio Logistics has collaborated with Wren Healthcare to offer a one-stop solution for CROs, sponsors, and study sites to support the continuation of clinical trial studies through home nursing and direct-to-patient IMP and sample logistics. It has become increasingly difficult for patients to attend study sites, and our homecare solution allows studies to continue by taking the trial to the patient.
Cambridge and Inverness, UK, 30th April 2020: TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with ODx (ODx Innovations Ltd), a company committed to developing a system for assessing urinary tract infections (UTIs). The collaboration is focussed on bringing ODx’ system to market through TTP’s Desktop Biology service.
Cambridge, UK, 29 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.
Cambridge, UK: In vitro fertilisation (IVF) treatment is now a global affair which involves patients, fertility clinics, embryologists and transportation specialists. Each country has different legislation relating to fertility treatments, and with many patients now finding themselves seeking IVF in a country which supports their specific needs, it is crucial to securely and reliably transport the invaluable frozen eggs, sperms or embryos from one fertility clinic to another for further treatment cycles.
One Nucleus adds power and influence as senior AstraZeneca executive, Penny James joins the region’s life science membership organisation’s Board
Cambridge, UK: 28 April 2020: One Nucleus, the Cambridge based not-for-profit membership organisation for the East of England-London life sciences cluster, is delighted to announce the appointment of Penny James as a Non-Executive Director. Penny is Chief Operating Officer, Biopharmaceuticals R&D at AstraZeneca, a role she took up in February 2019.
Cambridge, 27th April 2020: The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. The additional funding will further enhance the ability of the Babraham Research Campus to drive innovation in early science concepts and nurture new life science companies within the Cambridge cluster.
Cambridge, UK: Biocair, a specialist logistics company, has recently managed several urgent large-scale shipments of COVID-19 related protective equipment. The company is also supporting many companies and agencies with the swift transportation of testing kits, diagnostic specimens and medical devices.